Generate:Biomedicines

Research on the record

• 2026-10-27Generate:Biomedicines cuts a CAR's signalling tail to 45 amino acids, under a third of the clinical design, and reports stronger functionLevel 4 · Tested in the physical world
• 2025-12-01Generate:Biomedicines takes an AI-optimised asthma antibody into two Phase 3 trialsLevel 5 · Used in practice
• 2023-11-15Generate:Biomedicines publishes Chroma, a diffusion model that writes new protein structures and sequences to order, and makes 310 of its designs in the labLevel 4 · Tested in the physical world

Graded by how far the evidence went, not how good the result is. See the methodology.

Also on the timeline

• 2026-10-27Anthropic buys a one-person drug company and starts running drug programmes of its ownOrganizations
• 2026-10-13Zealand Pharma pays Generate Biomedicines $30M upfront to design multispecific proteins for obesityPartnerships
• 2026-02-26Generate:Biomedicines prices a $400M Nasdaq IPOCapital

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2026-02-26IPO · $400MconfirmedStated use: public listing on Nasdaq
• 2023-09-14Series C · $273MconfirmedWith Amgen, NVentures (NVIDIA), MAPS Capital (Mirae Asset), Pictet Alternative Advisors, Flagship Pioneering, Fidelity, ADIA (subsidiary), T. Rowe Price, ARCH Venture Partners, March CapitalStated use: multi-year runway to advance clinical programs and the platform
• 2021-11-18Series B · $370MconfirmedWith Flagship Pioneering, ADIA (subsidiary), Alaska Permanent Fund, ARCH Venture Partners, Fidelity, T. Rowe Price, Morningside Ventures, Altitude Life Science VenturesStated use: evolve the platform, scale the team, move programs toward IND

Each round links to its line on the funding record, with its source.

Also in Protein design on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
• 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
• 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
• 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
• 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
• 2026-03-20Helixon (Earendil Labs)Round (unnamed) · $787MAI protein modelling plus high-throughput experiments to design antibodies, especially bispecifics, which it licenses to Sanofi and Genentech and develops in-house.

All 15 in this field →